HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma.

Abstract
BACKGROUND The aim of this study was to compare nutrition-related adverse events and clinical outcomes of ifosfamide, carboplatin, and etoposide regimen (ICE therapy) and ranimustine, carboplatin, etoposide, and cyclophosphamide regimen (MCEC therapy) instituted as pretreatment for autologous peripheral blood stem cell transplantation. MATERIAL AND METHODS We enrolled patients who underwent autologous peripheral blood stem cell transplantation between 2007 and 2012. Outcomes were compared between ICE therapy (n=14) and MCEC therapy (n=14) in relation to nutrient balance, engraftment day, and length of hospital stay. In both groups, we compared the timing of nutrition-related adverse events with oral caloric intake, analyzed the correlation between length of hospital stay and duration of parenteral nutrition, and investigated the association between oral caloric intake and the proportion of parenteral nutrition energy in total calorie supply. Five-year survival was compared between the groups. RESULTS Compared with the MCEC group, the ICE group showed significant improvement in oral caloric intake, length of hospital stay, and timing of nutrition-related adverse events and oral calorie intake, but a delay in engraftment. Both groups showed a correlation between duration of parenteral nutrition and length of hospital stay (P=0.0001) and between oral caloric intake (P=0.0017) and parenteral nutrition energy sufficiency rate (r=-0.73, P=0.003; r=-0.76, P=0.002). Five-year survival was not significantly different between the groups (P=0.1355). CONCLUSIONS Our findings suggest that compared with MCEC therapy, ICE therapy improves nutrition-related adverse events and reduces hospital stay, conserving medical resources, with no significant improvement in long-term survival. The nutritional pathway may serve as a tool for objective evaluation of pretreatment for autologous peripheral blood stem cell transplantation.
AuthorsTakashi Aoyama, Osamu Imataki, Hidekazu Arai, Tetsuo Kume, Hitomi Shiozaki, Naomi Katsumata, Mariko Mori, Keiko Ishide, Takashi Ikeda
JournalMedical science monitor basic research (Med Sci Monit Basic Res) Vol. 24 Pg. 31-39 (Feb 05 2018) ISSN: 2325-4416 [Electronic] United States
PMID29398693 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Nitrosourea Compounds
  • Etoposide
  • Cyclophosphamide
  • Carboplatin
  • ranimustine
  • Ifosfamide
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
  • Carboplatin (therapeutic use)
  • Cyclophosphamide (therapeutic use)
  • Energy Intake
  • Etoposide (therapeutic use)
  • Female
  • Humans
  • Ifosfamide (therapeutic use)
  • Lymphoma (drug therapy)
  • Male
  • Middle Aged
  • Nitrosourea Compounds (therapeutic use)
  • Nutritional Physiological Phenomena
  • Peripheral Blood Stem Cell Transplantation
  • Survival Analysis
  • Transplantation, Autologous
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: